巴西真实世界环境中银屑病关节炎的药物持续性
Medication persistence for psoriatic arthritis in a Brazilian real-world setting.
作者信息
Ribeiro da Silva Michael Ruberson, Ribeiro Dos Santos Jéssica Barreto, Maciel Almeida Alessandra, Itria Alexander, Maria Kakehasi Adriana, Alvares Teodoro Juliana, de Assis Acurcio Francisco
机构信息
Department of Social Pharmacy, Postgraduate Program in Medicines & Pharmaceutical Assistance, College of Pharmacy, Federal University of Minas Gerais, President Antônio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil.
Department of Social Pharmacy, College of Pharmacy, Federal University of Minas Gerais, President Antônio Carlos Avenue, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil.
出版信息
Future Sci OA. 2019 Jan 18;5(2):FSO369. doi: 10.4155/fsoa-2018-0101. eCollection 2019 Feb.
AIM
To evaluate the persistence of biological (TNF inhibitor [anti-TNF]) and synthetic (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs]) antirheumatic agents for psoriatic arthritis and their associated factors.
METHODS
A historical cohort was developed. Persistence and associated factors were evaluated at 6 and 12 months.
RESULTS
A total of 161 patients were included. The anti-TNF treatment presented higher persistence as compared with csDMARDs at 6 (83.4 vs 50.8%; p < 0.05) and 12 months (66.4 vs 35.6%; p < 0.05). From anti-TNFs, adalimumab and etanercept presented similar persistence, along with leflunomide and methotrexate among the csDMARDs. The factors associated with non-persistence with regard to anti-TNF agents were female sex and use of infliximab.
CONCLUSION
Anti-TNF agents are important therapeutic alternatives and present lower rates of discontinuation as compared with csDMARDs.
目的
评估生物制剂（肿瘤坏死因子抑制剂[抗TNF]）和合成制剂（传统合成改善病情抗风湿药[csDMARDs]）治疗银屑病关节炎的持续性及其相关因素。
方法
建立一个历史性队列。在6个月和12个月时评估持续性及相关因素。
结果
共纳入161例患者。在6个月时（83.4%对50.8%；p<0.05）和12个月时（66.4%对35.6%；p<0.05），抗TNF治疗的持续性高于csDMARDs。在抗TNF药物中，阿达木单抗和依那西普的持续性相似，在csDMARDs中，来氟米特和甲氨蝶呤的持续性相似。与抗TNF药物治疗不持续相关的因素为女性及使用英夫利昔单抗。
结论
与csDMARDs相比，抗TNF药物是重要的治疗选择，停药率较低。
Zotero 插件